Zelira Therapeutics Valuation

Is G1G undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of G1G when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate G1G's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate G1G's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for G1G?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for G1G. This is calculated by dividing G1G's market cap by their current preferred multiple.
What is G1G's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	AU$5.45m

G1G key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	26.8x
Enterprise Value/EBITDA	-1.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does G1G's PS Ratio compare to its peers?

The above table shows the PS ratio for G1G vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.3x
B8FK Biofrontera	0.4x	n/a	€10.5m
SBX SynBiotic	5.4x	33.8%	€46.0m
APPH Apontis Pharma	2.1x	17.6%	€77.3m
0RX Redx Pharma	13.3x	-37.6%	€65.0m
G1G Zelira Therapeutics	19.5x	n/a	€5.4m

Price-To-Sales vs Peers: G1G is expensive based on its Price-To-Sales Ratio (19.5x) compared to the peer average (5.3x).

Price to Earnings Ratio vs Industry

How does G1G's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	22.3%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	22.3%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: G1G is expensive based on its Price-To-Sales Ratio (19.5x) compared to the European Pharmaceuticals industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is G1G's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

G1G PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	19.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate G1G's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.